Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have been given an average rating of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $11.71.
A number of equities analysts have recently weighed in on RANI shares. Oppenheimer began coverage on Rani Therapeutics in a report on Friday, August 2nd. They issued an “outperform” rating and a $17.00 target price on the stock. HC Wainwright decreased their price target on shares of Rani Therapeutics from $13.00 to $9.00 and set a “buy” rating for the company in a report on Friday, August 16th. Rodman & Renshaw initiated coverage on Rani Therapeutics in a research note on Thursday, June 13th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Maxim Group began coverage on Rani Therapeutics in a research report on Friday, June 14th. They set a “buy” rating and a $15.00 price objective for the company.
Get Our Latest Analysis on RANI
Institutional Investors Weigh In On Rani Therapeutics
Rani Therapeutics Stock Performance
Shares of RANI stock opened at $2.31 on Friday. The firm has a market capitalization of $116.47 million, a P/E ratio of -1.79 and a beta of 0.12. The company has a debt-to-equity ratio of 3.10, a current ratio of 1.93 and a quick ratio of 1.93. Rani Therapeutics has a 12 month low of $1.82 and a 12 month high of $8.75. The company’s fifty day moving average price is $2.56 and its two-hundred day moving average price is $3.88.
Rani Therapeutics (NASDAQ:RANI – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.03. On average, research analysts anticipate that Rani Therapeutics will post -0.98 earnings per share for the current fiscal year.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
See Also
- Five stocks we like better than Rani Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What is a Death Cross in Stocks?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- What is a Bond Market Holiday? How to Invest and Trade
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.